Anti-proliferative activity and mechanism of action of titanocene dichloride. by Christodoulou, C. V. et al.
British Joumal ofCancer (1998) 77(12), 2088-2097
© 1998 Cancer Research Campaign
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CRC Institute for Cancer Studies, The University of Birmingham Medical School, Birmingham B15 2TA, UK
Summary Development of resistance to cytotoxic agents is a major limitation to their clinical use. Novel compounds are synthesized with a
view to develop non-cross-resistant, less toxic and more potent activity. The detection of the anti-tumour properties of the inorganic compound
cisplatin stimulated a broad search for other metal-containing complexes. Titanocene dichloride was synthesized on this basis and has shown
potent anti-neoplastic activity in experimental animals. We have examined the in vitro activity of titanocene dichloride in two pairs of platinum-
sensitive and resistant human ovarian carcinoma cell lines, A2780/2780CP and CH1/CH1cisR, and in mutated p53- and bcl-2-transfected
clones of A2780 cells. A time- and concentration-dependent anti-proliferative effect was observed in all cell lines treated with titanocene
dichloride. The drug was found to significantly overcome platinum resistance in the 2780CP and the CH1 cisR cell lines and in the bcl-2 and
the mutant p53 transfectants of A2780 cells. Titanocene dichloride induced a block in late S/early G2 phase of the cell cycle; however
apoptotic cell death occurred from any phase of cycle. Titanium-DNA adducts were detected in A2780 cells treated with titanocene dichloride
using atomic absorption spectrometry, suggesting that DNA may be a target for this drug. In agreement with this finding, p53 accumulated
rapidly in drug-treated A2780 cells, indicative of a role for titanocene dichloride as a DNA-damaging agent. We have also performed studies
to determine whether titanocene dichloride could demonstrate synergy with other cytotoxic agents in vitro. Isobologram analysis of
cytotoxicity data obtained suggests that the combination of titanocene dichloride and 5-fluorouracil (5-FU) is synergistic. The potent in vivo
anti-tumour activity of this compound, supported by the encouraging results from two phase clinical trials, suggests that titanocene dichloride
could be a promising novel chemotherapeutic agent.
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After the discovery of its anti-tumour activity, cis-diammine-
dichloroplatinum(II) (cisplatin, cDDP) has become one of the
most widely used drugs for the treatment ofcancer. Its importance
was derived largely from its ability to confer complete responses
in patients with advanced testicular cancer, and it was subse-
quently found to exhibit significant therapeutic efficacy in ovarian,
uterus, bladder, and head and neck cancer (Rosenberg et al, 1969;
Calvert et al, 1995). The remarkable anti-tumour effects of
cisplatin coincide, however, with marked toxic effects, including
neurotoxicity, nephrotoxicity and severe emetic toxicity. In addi-
tion, there is a propensity for tumours to develop resistance to
platinum, which constitutes a major problem in its clinical use.
The effectiveness of this drug against a wide range of human
tumours, as well as its limitations, has generated a broad interest in
developing new platinum complexes with lower toxicity and
improved activity and spectrum.
Despite some 25 years ofeffort, there has been little progress to
date in developing new platinum complexes with the above
characteristics. Thus far, the most effective second-generation
platinum compound to have been developed is carboplatin. Its
spectrum of anti-tumour activity is not different from that of
cisplatin, but it presents significantly reduced nephrotoxicity.
However, the results of both randomized cisplatin vs carboplatin
and cross-over studies performed in ovarian cancer show that both
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compounds are effective against essentially the same population
of tumours (Gore et al, 1989; Eisenhauer et al, 1990; advanced
Ovarian Cancer Trialists Group, 1991). These reports, together
with accumulating in vitro data suggest that carboplatin is not
capable ofcircumventing cisplatin resistance.
In addition to platinum, other metal-containing complexes have
been synthesized and subjected to tumour screening. The anti-
tumour activity of the organometallic compound titanocene
dichloride [cyclopentadienyl-dichloro titanium(IV)] has been
recognized and well documented in experimental animals. Thus,
in a number of transplanted tumours of murine origin, such as
Ehrlich ascites, sarcoma, colon adenocarcinoma, melanoma and
lung carcinoma models, titanocene dichloride was highly effective
(Kopf-Maier and Kopf, 1988; Kopf-Maier, 1989a). Moreover, the
growth of xenotransplanted human tumours of colon, lung, breast
and head and neck, as well as autochthonous chemically induced
colorectal tumours in rats, were markedly reduced by this
compound (Kopf-Maier et al, 1985; Kopf-Maier, 1987, 1989b).
The pattern of organ toxicity of titanocene dichloride in these
animals was found to be different from that of cisplatin, with
hepatic toxicity being the most prominent side-effect of
titanocene; unlike cisplatin and carboplatin, however, no severe
nephrotoxicity or myelotoxicity was observed (Kopf-Maier and
Funke-Kaiser, 1986; Kopf-Maier and Geralch, 1986; Kopf-Maier
and Kopf, 1988; Kopf-Maier et al, 1988; K6pf-Maier, 1989a).
Titanocene dichloride has recently entered phase I clinical trial
with promising results (Christodoulou et al, submitted). The dose-
limiting toxicities seen following a weekly schedule of 1-h
infusion were reversible nephrotoxicity and hepatotoxicity. The
pharmacokinetics of titanocene dichloride appear to be complex
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and are described by a three-compartment model fortotal titanium.
Peak titanium levels are in the range 25-75 gM at the maximum-
tolerated dose of 140 mg m-2 per week.
While the anti-tumour effects oftitanocene dichloride on exper-
imental animals have been well documented and the phase I clin-
ical trial so far suggests a potential role for this compound as an
anti-tumour agent, little is known about its in vitro properties and
mode of action (Harstrick et al, 1993). In this study, we have
demonstrated that titanocene dichloride confers potent anti-prolif-
erative properties in vitro and may partly reverse platinum resis-
tance in ovarian tumour cell lines. The cytostatic and cytotoxic
effects of the drug could result from its observed ability to form
DNA adducts and to induce cell cycle arrest and apoptosis.
Understanding the mechanism of action of this novel chemothera-
peutic agent may contribute to the development of more effective
anti-cancer drugs.
MATERIALS AND METHODS
Cell lines, plasmids, transfections
The human ovarian carcinoma cell line A2780 and the acquired
platinum-resistant 2780CP (Behrens et al, 1987) were kindly
provided by Dr J Plumb (University of Glasgow, Glasgow, UK).
These lines were continuously maintained in RPMI medium
supplemented with 10% fetal calf sesum (FCS) (Flow, UK), 1%
glutamine and 1% penicillin/streptomycin. The CHI and CH1-
cisR cell lines (Kelland et al, 1992) were kindly provided by Dr L
Kelland (Institute for Cancer Research, Surrey, UK) and cultured
in similar conditions. Development and characterization of A2780
clones expressing bc1-2 or temperature-sensitive p53 have been
previously described (Eliopoulos et al, 1995).
Anti-cancer agents and chemicals
Titanocene dichloride [cyclopentadienyl-dichloro-titanium(IV)]
was provided by Medac (Hamburg, Germany). The formulation
was supplied as a freeze-dried powder in vials containing 50 mg of
drug. It was stored at 4°C, protected from light. The reconstitution
of the compound was carried out in 0.9% sodium chloride at a
concentration of 2 mg ml-'. The final solution was strictly
protected from light and was used immediately. The structure of
the drug is given in Figure 1.
MTT assay for cytotoxicity
Cytotoxicity was estimated using the colorimetric MTT conver-
sion assay ofMosmann (1983). Briefly, cells were trypsinized and
plated out at a density of 3000-5000 cells per well into a 96-well
plate and allowed to attach overnight. The next day, the cells were
treated for 2 h with various concentrations oftitanocene dichloride
and/or other cytotoxic agents, washed with phosphate-buffered
saline (PBS), and 200 tl of fresh complete medium were added.
Forty-eight hours later, 20 tl of 5 mg ml-' MTT (3,(4,4-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma,
Poole, UK) in PBS were added in each well incubated for 4 h at
37°C, and the formazan crystals fromed were dissolved in di-
methyl sulphoxide (DMSO). The optical density (OD) was
recorded at 550 nm on a Becton Dickinson Multisan. The IC90
(inhibitory concentration 50%) values were the drug concentra-
tions inducing 50% reduction in the optical density.
[3H]Thymidine incorporation assay
Cells were plated and treated as described above and pulsed for the
last 4 h with 0.33 gCi [3H]thymidine (Amersham). The cells were
then washed twice with PBS, trypsinized and harvested using
a Skatron cell harvester. [3H]Thymidine incorporation was
measured on a Pharmacia Betaplate counter.
Calculation of synergy
A2780 cells were treated with various concentrations oftitanocene
dichloride (0, 10, 50, 100, 200 gM) in the presence of increasing
concentrations of 5-fluorouracil (5-FU) (0, 10, 50, 100, 500 gM),
doxorubicin (0, 0.1, 1, 5, 10 tM) or carboplatin (0, 10, 50, 100,
500 gM). Cytotoxicity was estimated using MTT conversion
assays as described above. Synergy was calculated by isobologram
analysis according to the method ofBerenbaum (1981).
Flow cytometric analysis of DNA content
Cells in monolayer culture were harvested, washed, fixed in 1%
neutral-buffered formalin (NBF) and stained with 5 ,ug ml-'
propidium iodide (PI). Fluorescence intensities were determined
by quantitative flow cytometry and profiles were generated on a
Coulter Epics-Profile II analyser. Coulter DNA-Cytologic Analysis
software was used to calculate the cell cycle and S-phase fraction.
Assays for the detection of apoptotic cell death
Quantification of DNA fragmentation was determined by flow
cytometry using the TUNEL (TdT) assay, as previously described
(Gorczyca et al, 1993; Eliopoulos et al, 1996). A2780 cells treated
with titanocene dichloride and untreated controls were fixed in 2%
paraformaldehyde, permeabilized in 70% ethanol and incubated in
1 x TdT buffer containing 10 U ofTdT (terminal deoxynucleotidyl
transferase) (Gibco, UK) and 2 mm digoxigenin-11-dUTP
(Boehringer, UK) for 35 min at 37°C, followed by a 30-min
incubation with 0.1% Triton X-100 and 5% non-fat milk. The cells
were finally stained with 5 mg ml-' propidium iodide (PI), and the
P1 (red, x-axis) and FITC (green, y-axis) fluorescence were then
analysed on a Becton Dickinson FACScan. Specific DNA frag-
mentation is the percentage green fluorescence in cells treated with
titanocene dichloride after subtraction of background green fluo-
rescence in control cultures.
For the electrophoretic characterization of DNA fragmentation,
approximately 106 cells were lysed in a solution containing 10 mM
EDTA, 50 mm Tris (pH 8), 0.5% N-Lauroyl-sarkosine (Sigma,
Poole, UK) and 0.5 mg ml-' Proteinase-K (Boehringer) and incu-
bated for 1 h in 50°C. RNAase at a concentration of 0.5 mg ml-'
(Sigma, Poole, UK) was then added and the mixture was further
incubated for 1 h. After the addition of 1Ogl of a solution
containing 0.01% bromophenol blue, 10 mm EDTA and 0.1% LMP
agarose, the samples were analysed on a 2% agarose gel and visual-
ized by ethidium bromide staining. Both attached and floating cells
from titanocene dichloride-treated cultures were analysed.
DNA extraction
DNA extracts from tissue specimens were prepared as described
by Sambrook et al (1989), slightly modified (Eliopoulos and
Spandidos, 1994). Briefly, treated cells or control cultures were
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Table 1 IC50 values for ovarian tumour cell lines treated with titanocene dichloride (TD) or cisplatin for 2 h, as determined by MTT
cytotxicity assays
Titanocene dichloride Cisplatin
Cell line IC50 (M) Resistance IC50(M) Resistance
factor factor
A2780 5.7 x 10-4 (±1.3) - 4.0 x 10- (+0.2) -
2780 CP 8.4 x 10-4 (±0.9) 1.47 5.1 x 10-5 (+0.3) 12.7
A2780bcI-2/CI.14 6.4 x 104 (±1.0) 1.12 1.2 x 10-5 (±0.3) 3.0
A2780bcl-2/CI.10 6.6 x 104 (±1.0) 1.15 1.4 x 10-5 (+0.3) 3.5
A2780tsp53/CI.1 (37.50C) 6.3 x 104 (+1.3) 1.10 7.5 x 10-6 (+0.5) 1.8
CH1 1.9 x 104 (+0.9) - ND -
CH1 cisR 3.1 x 10-4 (±1.1) 1.60 ND
Values represent means of at least three independent experiments. ND, not determined.
Ti
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9 M urea and subsequent sonication. Protein concentration was
estimated using the Biorad protein assay. Then, 100 lg of total
protein was separated on a 10% SDS-polyacrylamide gel in a Tris-
glycine running buffer. After electrophoresis, the proteins were
electroblotted onto nitrocellulose (85 V, 5 h). The blots were
blocked in 5% non-fat milk in PBS-Tween (blotto) and incubated
overnight with antibody properly diluted in blocking solution.
Immune complexes were detected with [1251]Protein-A
(Amersham, UK) after incubation with appropriate immuno-
globulin (IgG). Antibody used was the PAbl801 mouse anti-
human p53 (gift from Professor D Lane, Department of
Biochemistry, University ofDundee, UK).
Figure 1 Chemical structure of titanocene dichloride [cyclopentadienyl-
dichloro-titanium (IV)]
incubated overnight in lysis solution (10 mM Tris, pH 7.8, 150 mM
sodium chloride, 0.5% sodium dodecyl sulphate (SDS) and
100 mg ml-' proteinase-K) at 37°C. After two phenol-chloroform
extractions, the aqueous phase was removed and incubated for 2 h
with 100 ,ug ml-' pancreatic RNAase (Sigma) at 37°C and for an
additional 2-h period with 100 ltg ml-' proteinase-K (Boehringer)
followed by phenol-chloroform extraction twice. The aqueous
phase was then removed and the DNA was precipitated with
ethanol. The DNA was washed with 70% ethanol, dried briefly,
resuspended in sterile water and estimated photometrically at
260 nm using an LKB 4054 spectrophotometer.
Detection of titanium-DNA adducts
DNA-bound titanium was measured using electrothermal atomiza-
tion atomic absorption spectrometry on a Varian Spectra AA-400
equipped with deuterium background correction. Analysis was
performed directly after dilution of the DNA solutions with 0.1%
HNO3. For calibration identically-treated matrix-matched stan-
dards were used. Standards were prepared using inorganic titanium
(BDH, Poole, UK), the analytical behaviour of this form of the
element having been found to match that of titanium present in
solutions oftitanocene dichloride in 0.1% nitric acid.
Protein extraction and Western blot analysis
Cell protein extracts were prepared by lysing cells into a buffer
containing 50 mM Tris (pH 6.8), 0.15 M f-mercaptoethanol and
RESULTS
Titanocene dichloride exhibits anti-proliferative activity
in vitro
In order to determine whether titanocene dichloride confers anti-
proliferative properties in vitro, A2780 ovarian carcinoma cells
were treated for 2 h with various drug concentrations (1 x 104-
2 x 10- M), and cell viability was assessed 48 h later by MTT
conversion assays. Analysis ofthe dose-response curves (Figure 2)
indicated that titanocene dichloride is effective in a rather narrow
range ofconcentrations, as determined by the inability of the drug
to induce cell killing in concentrations lower than lx 104 M and by
the steep pattern ofthe slope ofthe cytotoxicity curve. Under these
experimental conditions, the IC50 value for the titanocene-treated
A2780 cells was 5.7 (±1.3) x 104 M (Table 1), while the corre-
sponding values for cisplatin or carboplatin-treated A2780 cells
were 4.0 (±0.2) x 10- M and 2.5 (±0.6) x 10-4 M respectively
(Eliopoulos et al, 1995 and data not shown). The IC5 values after a
48-h continuous exposure to titanocene dichloride, cisplatin or
carboplatin were also determined and were 2.8 (±1.0) x 10X, 0.8
(±0.4) x I0" and 1.2 (±0.5) x 104 M respectively. Similar results
were obtained when [3H]thymidine incorporation assays were
performed (Figure 2C). In addition, treatment of CH1 ovarian
tumour cells with titanocene dichloride induced a concentration-
dependent cytotoxic effect, with an IC50 value of 1.9 x 104 M
(Table 1). The pattern ofdose-response curve fordrug-treated CH1
cells was similar to that of A2780 (data not shown). The above
results suggest that titanocene dichloride confers antiproliferative
properties in vitro, however the drug concentrations necessary to
inhibit cell growth are significantly higher than those ofcisplatin.
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Figure 2 (A and B) Cytotoxicity curves from typical MTT assays showing
the effect of titanocene dichloride (TD) on the viability of A2780 ovarian cell
line, a bcl-2 transfectant (A2780bcl-2/CI.14), a tsp53 transfectant
(A2780tsp53/Cl.1) expressing mutated p53 and the resistant variant 2780CP.
(C) Growth curves from a typical [3H]thymidine incorporation assay showing
the effect of TD on the proliferation of A2780, 2780CP andA2780bcl-2/CI.14
cells. The shift of the curve to the right is characteristic of an increase in
viability. At least three independent experiments were performed and gave
similar results
Titanocene dichloride significantly overcomes platinum
resistance in vitro
In order to determine whether titanocene dichloride overcomes
platinum resistance in vitro, the anti-proliferative effects of the
drug on cisplatin-resistant A2780 and CHI variants (2780CP and
CH1 cisR respectively) were examined. As ovarian tumours often
develop resistance to platinum, these lines present a good model
for screening novel compounds with a potential of overcoming
resistance. In addition, the above cell lines have been well charac-
terized in terms of mechanism of resistance. Thus, cisplatin resis-
tance in 2780CP and CHlcisR cells appears to be associated with
increased DNA repair (Masuda et al, 1990; Kelland et al, 1992),
although we have also noticed increased glutathione levels in
2780CP cells (AG Eliopoulos, unpublished observations).
When 2780CP cells were treated with titanocene dichloride,
a concentration-dependent antiproliferative effect was observed
using MTT conversion or[3H]thymidine incorporation assays
(Figures 2A and C). The IC50value, as determined by MTT assays
was 8.4(±0.9)xI04M (Table 1), while the corresponding value for
cisplatin-treated 2780CP cells has been previously found to be
5.1 (±0.3) x 10-5 M (Eliopoulos et al, 1995). Thus, while 2780CP
cells are 12.7 times more resistant to platinum than their sensitive
parental counterpart, the cisplatin-resistant variant appears to be
only1.5-fold more resistant to titanocene dichloride compared
with A2780 cells. Similar results were obtained forCHI/CHlcisR
cells and are summarized in Table 1. The observed dramatic
decrease in resistance factor suggests that titanocene dichloride
confers a potent antiproliferative effect on platinum-resistant
ovarian tumour cell lines.
Over the last few years, there has been increasing evidence that
expression of certain anti-apoptotic genes, such as bcl-2 and p53,
may affect the cellular response to chemotherapy and therefore
modulate the sensitivity of cells to anti-cancer drugs (Dive and
Hickman, 1991; Dive and Wyllie, 1993; Martin and Green, 1994).
Thus, we have recently shown that bcl-2 and p53 are frequently
expressed in ovarian carcinomas (Herod et al, 1996), and cis-
platin-resistant ovarian tumour cell lines have elevated levels of
these anti-apoptotic proteins compared with their normal counter-
parts (Eliopoulos et al, 1995). In addition, transfection of A2780
cells with a bcl-2- or a temperature-sensitive mutant p53 (ts p53)-
expressing plasmid increased platinum resistance by 2.1 to 3.5-
and 1.7- to 2.4-fold respectively (Eliopoulos et al, 1995).
Examination of two of these bcl-2 clones (A2780bcl-2/Cl.10 and
Cl. 14) forresponse to titanocene dichloride showed that this drug
may be very effective against resistance conferred by bcl-2. In
each experiment performed, the dose-response curve of
titanocene-treated A2780bcl-2/Cl. 14 vs A2780 cells was consis-
tently shifted to the right (Figure 2B and C), which suggests that
bcl-2 confers some degree ofresistance; however the difference in
IC50 values is too small to support a biological significance. Thus,
while cisplatin-treated A2780bcl-2 cells were approximately
three-fold more resistant than the parental line, the resistant factor
for titanocene-treated bcl-2-expressing cells was 1.2 (Table 1),
which suggests that titanocene dichloride may overcome bcl-2-
mediated platinum resistance.
As mutated p53 confers a survival advantage against
chemotherapy (Hainaut, 1995), the response of tsp53-transfected
A2780 cells (A2780tsp53/Cl. 1) to titanocene was examined using
MTT assays. At the permissive temperature of37.5°C, at which
the p53 protein is predominantly in the mutant conformation, the
British Journal of Cancer(1998) 77(12), 2088-2097
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Figure 3 (A) DNA content of A2780 cells treated with 1 x 10-3 M titanocene dichloride (TD) for 2 h and collected at various time points post treatment (6, 15,
24, 30, 48 h), as assessed by flow cytometry. TD induced a significant block in late S-/early G2 phase. (B) Cell cycle changes in A2780, 2780CP and A2780bcl-
2/CI.14 after a 2-h exposure to 1 x 10-3 M TD. The percentage of cells inGj, S and G/M phases of the cell cycle is shown. Five independent experiments were
performed and gave similar results
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Figure 4 (A) Formation of low-molecular-weight DNA in A2780 ovarian tumour cells at 24 h post treatment with 1 x 10-5, 1 x 10- or 1 x 10-3 M titanocene
dichloride (TD) for 2 h. DNA ladders were not detected in control untreated cells (lane 1). (B) Apoptotic A2780 cells at 6, 15 and 24 h after a 2 h exposure to
1 x 10-3 M TD, as determined with the TdT (TUNEL) assay. The A2780 cells apoptose from any phase of the cell cycle in response to titanocene treatment.
The percentage of apoptotic cells is given on the top right-hand side of the graphs
dose-response curves for mutated p53-expressing vs control in cisplatin resistance (Eliopoulos et al, 1995), these results
A2780 cells were almost identical (Figure 2B). As we have previ- suggest that titanocene dichloride overcomes mutated pS3-
ously shown that A2780tsp53/Cl. 1 cells confer a 1.8-fold increase mediated platinum resistance in ovarian tumour cell lines.
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Figure 5 (A) Kinetics of formation of titanium-DNA adducts. A2780 cells
were treated with 1 x 10-3 M titanocene dichloride (TD) for 0, 2, 6 or 15 h and
isolated DNA was subjected to atomic absorption spectrometry for the
detection of titanium bound to DNA. The data are representative of two
independent experiments. (B and C) Induction of p53 protein levels in
response to titanocene dichloride treatment. A2780 cells were collected at
12 h post treatment with various drug concentrations and analysed for p53
expression by immunoblot (B). Alternatively, A2780 cells were exposed to
1 X 10-3 M TD for 2 h and analysed at 2, 6, 12 or 24 h later for p53 levels (C).
Data are representative of at least three independent experiments
IC90 values (Table 1) were calculated and subjected to two-way
analysis of variance. This was carried out to assess the relative
resistance of the different cell lines to titanocene dichloride. This
analysis allows the variation between the cell lines that are under
investigation while adjusting for the variation between the experi-
ments. Multiple comparison tests showed that the 2780CP line has
significantly higher IC90 value compared with the other three lines
(A2780, A2780bcl-2 and A2780tsp53), which do not differ. The
above difference was observed after 2 h (P = 0.01 for MTT assays,
P = 0.08 for [3H]thymidine) and 48 h drug exposure (P = 0.002).
Titanocene dichloride induces cell cycle arrest in
ovarian tumour cell lines
In order to determine whether the anti-proliferative effects of
titanocene dichloride involve growth arrest at specific phases of
the cell cycle, A2780 cells were collected at various time points (0,
6, 15, 24, 30, 48 h) after treatment with lXlO-3 M titanocene and
analysed for their DNA content using flow cytometry. As shown in
Figure 3, titanocene dichloride induced a significant block in late
S/early G, phase of the cell cycle at 15 and 24 h after treatment.
This block was however transient and cells returned to normal
cycling by 48 h after exposure to the drug. Thus, the percentage of
0 0.2 0.4 0.6 0.8 1
TD (IC50 units)
Figure 6 (A) Cytotoxicity curves from a representative MTT assay showing
the effects of increasing concentrations of 5-fluorouracil (5-FU) in combination
with various concentrations of titanocene dichloride (TD) on the viability of
A2780 ovarian cell line. In this experiment, the IC50 values for the two drugs
were 4.9 and 5.1xl 0-4 M respectively. (B) TD and 5-FU interaction data
presented by isobol plot. After determining the IC50 concentrations for the
individual drugs, a range of fractions of the IC50 value for TD was selected.
For each of these fractions, we then determined the amount of 5-FU
necessary to restore the total drug effect to 50% growth inhibition. The isobol
plots the amounts of 5-FU (as a fraction of its IC50) that give the 50% inhibition
of cell growth. The IC50 values reported represent the mean values of four
independent experiments using various combinations of TD and 5-FU for the
treatment of human ovarian carcinoma cells A2780. The 5-FU and the TD
concentrations used in these experiments varied from 1 x 10-5 to 1 x 10-3 M
A2780 cells in G,/M phase increased from 10.7 at 0 h to 14.7 and
33.6 at 15 and 24 h respectively. 2780CP and A2780bcl-2/Cl.14
cells were also examined for cell cycle block upon titanocene
treatment and gave similar results (Figure 3B).
Titanocene dichloride induces apoptosis in ovarian
tumour cell lines
Apoptosis is a mode of cell death observed in a variety of cell types
after treatment with chemotherapeutic agents. In order to determine
whether titanocene dichloride also induces apoptosis in vitro, A2780
cells were treated for 2 h with 1 x 10-5 M, 1 x 104 M or I x l0- M
titanocene and analysed 24 h later for DNA fragmentation using
agarose gel electrophoresis. Formation of small-molecular-weight
DNA (DNA ladders) is a hallmark ofapoptotic cell death. As shown
in Figure 4A, titanocene dichloride induced formation of DNA
ladders at 1 x IO-3 M and to a lesser extent at 1 x 104 M but not at the
lower concentration of 1 x 10-5 M. DNA ladders were not detected in
control, untreated cultures (Figure 4A, lane 1).
As this agarose electrophoresis assay does not allow correlation
between DNA fragmentation and position in the cell cycle, the
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TdT (TUNEL) assay was performed to determine whether
titanocene-treated A2780 cells apoptose at specific phases of the
cell cycle. A2780 cells were exposed to 1 x 10-3 M titanocene
dichloride for 2 h and analysed 6, 15 or 24 h later for DNA strand
breaks and DNA content, as described in Materials and methods.
Double-colour flow cytometric analysis showed a significant
increase in green-fluorescent apoptotic cells at 15 and 24 h and
revealed that titanocene induces apoptosis from any phase of the
cell cycle (Figure 4B).
Formation of titanium-DNA adducts and up-regulation
of p53 in titanocene-treated A2780 cells
Previous studies have documented that DNA is the primary target
for cisplatin and that formation of platinum-DNA adducts is
necessary for the cytotoxic action of the drug. In order to deter-
mine whether titanocene dichloride also forms DNA adducts,
A2780 cells were exposed to 1 x 10-3 M titanocene dichloride for
2, 6 or 15 h, and DNA was extracted and purified using a standard
procedure. Titanium bound to DNA was then measured using
atomic absorption spectrometry. Titanium was detected in DNA
isolated from titanocene dichloride-treated but not in DNA from
untreated control cells (Figure 5A). In addition, the accumulation
of titanium-DNA adducts increased with the duration of the
exposure to the drug, being most prominent at 15 h.
As formation of platinum-DNA complexes and subsequent
DNA damage lead to nuclear accumulation of p53 (Kastan et al,
1991; Eliopoulos et al, 1995), the effect oftitanocene on p53 levels
in A2780 cells was determined. Protein extracts isolated from
titanocene-treated cells were subjected to immunoblot analysis
using an anti-p53-specific monoclonal antibody. As shown in
Figures SB and C, a concentration- and time-dependent increase in
p53 levels was observed. The most prominent increase occurred
at 15 h of treatment with 1 x 10-3 M titanocene dichloride.
Immunofluorescence staining ofdrug-treated A2780 cells verified
the accumulation of the protein in the nucleus.
Titanocene dichloride exhibits synergistic cytotoxicity
with 5-FU
The observed lack of myelosuppression in animal models makes
titanocene dichloride a clinically interesting cytotoxic compound
as it could potentially allow combinations with other drugs. To
determine whether titanocene could exhibit synergy with other
agents commonly used in cancer chemotherapy, A2780 cells were
exposed to combinations of titanocene dichloride with 5-fluoro-
uracil (5-FU), doxorubicin or carboplatin. Interestingly, low
concentrations of titanocene, which have little or no effect on
A2780 viability, significantly potentiated the antiproliferative
action of 5-FU (Figure 6A). Isobologram analysis revealed
synergy with this compound (Figure 6B). Titanocene dichloride,
however, failed to increase the cytotoxicity of doxorubicin or
carboplatin (data not shown).
DISCUSSION
Recent advances in the study of molecular and cellular biology of
cancer have allowed the identification of novel biochemical and
molecular targets for the treatment of malignancies and drug-
discovery programs are directed towards rational development.
Various agents that show interesting activity in recent clinical
trials have been derived from drug screening, such as paclitaxel,
but also from chemical synthesis of analogues of existing anti-
neoplastic drugs, such as oxaliplatin. It is important to use the
advances in cancer biology to gain more mechanistic information
about old and new cytotoxic agents. This would allow the devel-
opment of novel, more potent drugs and/or the modification of
current therapeutic strategies.
The in vivo anti-tumour activity of the organometallic
compound titanocene dichloride has been previously documented
in experimental animals, however little is known about its mode of
action. Our studies indicate that this drug exhibits limited anti-
proliferative activity in vitro, compared with platinum compounds
commonly used in chemotherapeutic regimens. Thus, in A2780
and CH1 ovarian tumour cell lines, titanocene appears to be
approximately 100- and twofold less potent than cisplatin and
carboplatin respectively. Interestingly, however, titanocene dichlo-
ride was found to significantly overcome cisplatin resistance in
ovarian carcinoma cell lines. Thus, while 2780CP cells are 12.7-
fold more resistant to cisplatin than their parental, sensitive coun-
terpart, they were found to be only 1.5-fold more resistant in
response to titanocene. As platinum resistance in 2780CP and
CH1-cisR cells involves predominantly increased DNA repair, the
cytotoxic action of titanocene may involve mechanisms different
from those of cisplatin. In this context, it is interesting that, while
cisplatin is known to mediate an early S-phase block in a number
of cell lines, including A2780 (Andrews and Howell, 1990;
Eliopoulos et al, 1995), titanocene dichloride induced a late S/
early G, phase block in the cell cycle. The G, arrest may represent
a phase at which repair of damage occurs before the drug-treated
cells enter mitosis.
The observed IC 50 values of titanocene dichloride were in the
range 200-800 gM, which are in agreement with a previous report
(Hastrick et al, 1993). While its in vitro antiproliferative effects are
rather limited, titanocene dichloride has demonstrated impressive
in vivo activity as measured by tumour regression in animal
models. In addition, our phase I clinical trial data with this
compound has shown that blood peak levels of titanium are in the
range 25-75 gM and anti-tumour activity was seen (Christodoulou
et al, submitted). At present it is unclear why titanocene dichloride
appears to be more potent in vivo rather than in vitro. While this
compound is stable at low pH (pH < 3), it undergoes rapid aqua-
tion at physiological pH and formation of an as yet undetected
drug metabolite in vivo is possible.
Clinical drug resistance is likely to be multifactorial but a
unifying feature may well be the failure of tumour cells to engage
the process of apoptosis (Dive and Hickman, 1991; Dive and
Wyllie, 1993; Martin and Green, 1994), and certain gene products
are known to influence this event. Thus, overexpression ofbcl-2 in
high-grade follicular lymphomas due to a t(14;18) translocation
may be associated with development of resistance to chemo-
therapy. While the role of bcl-2 in regulation of drug-induced
apoptosis is supported by a number of in vitro studies in
haemopoietic cell systems, the effect of this protein on the sensi-
tivity of carcinoma cells to chemotherapy remains less known.
Expression of mutated p53 has also been shown to protect from
apoptosis, although not to the same extent as bcl-2 (Hainaut,
1995). We have previously shown that ovarian carcinoma cells
that are resistant to cisplatin naturally overexpress bcl-2, p53 or
both proteins, suggesting an important role for these genes in
acquired resistance (Eliopoulos et al, 1995). Expression of exoge-
nous bcl-2 or mutated p53 in the ovarian cell line A2780 also
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resulted in decreased sensitivity to cisplatin. Interestingly, treat-
ment of A2780 cells transfected with bcl-2 or mutated p53 with
high concentrations of titanocene dichloride, abrogated platinum
resistance mediated by these anti-apoptotic proteins. The above
observations may be important for the therapy of tumours that
develop resistance to platinum, and we are currently examining
this possibility in experimental animals bearing 2780CP- or
A2780bcl-2-based tumours.
While the cytostatic effects of titanocene dichloride could be
attributed to a specific block in the cell cycle, it appears that the
drug induces cell killing from any phase of cycle. Similar results
have been reported for some but not all anti-cancer drugs. DNA is
the critical target for cisplatin and various platinum-DNA adducts
are known to be formed in cell lines treated with this drug (i.e.
monofunctional, intrastrand, interstrand, intermolecular) (Roberts
et al, 1986; Andrews and Howell, 1990). Interestingly, formation
of titanocene-DNA adducts was also observed in titanocene
dichloride-treated A2780 cells. The nature of these adducts is
under investigation. Preliminary results indicate a significant time-
and dose-dependent formation of DNA single strand breaks but
only a very low amount of DNA cross-linking in drug-treated
cells. Formation of DNA cross-linking was also observed in
isolated DNA treated in vitro with titanocene; however this effect
was found to be significantly lower than that of cisplatin (JA
Hartley, AG Eliopoulos and DJ Kerr, unpublished observations).
Titanocene-DNA adducts may directly mediate DNA damage,
which could lead to nuclear accumulation ofp53. Previous studies
have documented the rapid induction of p53 in response to DNA-
damaging agents, including UV radiation and various chemothera-
peutic agents, and have attributed to p53 the role of the 'guardian
of the genome' (Kastan et al, 1991; Lane, 1992). In agreement
with these reports, titanocene dichloride was found to induce
nuclear accumulation of p53 in a dose- and time-dependent
manner. Glutathione depletion using Buthionine sulphoximin
(BSO) leads to an increase in titanocene dichloride-mediated cyto-
toxicity (Harstrick et al, 1993), and our preliminary results suggest
that treatment of A2780 cells with titanocene dichloride in the
presence of BSO significantly enhances p53 accumulation.
Titanocene dichloride has an interesting toxicological profile and
does not cause myelosuppression; therefore it could be safely
combined with other cytotoxics. A potentially interesting observa-
tion from a clinical point of view is that titanocene dichloride
demonstrates synergy with 5-FU, a thymidylate synthetase
inhibitor, in conferring cytotoxic effects in A2780 cells. No syner-
gistic interaction was found, however, with carboplatin or doxo-
rubicin. This may be particularly important for the treatment of
metastatic colon adenocarcinoma, as there is lack ofeffective treat-
ment for this type of malignancy. 5-FU is the cornerstone of thera-
peutic regimes against colon cancer but it produces only a 15-30%
response rate in combination with leucovorin. Similar response
rates are produced by tomudex, which is a new thymidylate
synthetase inhibitor with a more favourable toxicological profile
and a more convenient way of administration. Oxaliplatin, a novel
platinum analogue, which, in combination with 5-FU/folinic acid,
has shown promising results in phase II and III clinical trials (Levi
et al, 1995), has demonstrated potent cytotoxic activity against
colorectal carcinoma cell lines either alone or in synergy with 5-
FU. In addition, human colon xenografts have been highly sensitive
to oxaliplatin and no cross-resistance to cisplatin has been observed
(Mathe et al, 1989; Tashiro et al, 1989; Dorr and Von Hoff, 1993;
Pendyala and Creaven, 1993). By analogy, Kopf-Maier and
colleagues (1985) have demonstrated impressive anti-tumour
activity of titanocene dichloride against human tumour xenografts
ofcolon adenocarcinoma, and our preliminary in vitro data suggest
that this drug is also effective against a number ofcolon cancer cell
lines. As we have noted a synergistic effect with 5-FU and
titanocene dichloride, it would be particularly attractive to test this
combination in metastatic colorectal cancer. Studies addressing this
question in experimental animals are under way.
In summary, titanocene dichloride is a novel drug with inter-
esting in vitro characteristics. The elucidation of its precise mecha-
nism of action may lead to the rational development of other more
active titanium analogues. So far, titanocene dichloride has been
tested in two phase I clinical trials, one in Germany (Kortel et al,
1996) and another in our Institute (Christodoulou et al, submitted),
which have given promising results, and we plan a phase II study in
metastatic colon cancer in combination with 5-FU.
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